Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has...

Full description

Saved in:
Bibliographic Details
Published in:Onco Targets Ther
Main Authors: Baldini, Capucine, Champiat, Stéphane, Vuagnat, Perrine, Massard, Christophe
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2019
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6452813/
https://ncbi.nlm.nih.gov/pubmed/31040693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S141040
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items